Ischemic vs. Non-Ischemic CRVO: Why the Difference Matters
Ischemic and Non-Ischemic CRVO at a Glance
Some changes need same day care. Call your eye doctor right away if you notice any of these.
- Severe eye pain, or a red and painful eye.
- Halos around lights, with new blur.
- A fast drop in vision over a day.
- New floaters, or a shower of floaters.
- A dark curtain or shadow in your view.
- Eye pain with a headache or nausea.
Most people never get these signs. In more severe cases, you can feel pain and pressure in the eye, and floaters can appear1. Both can be treated. Both do better when found early. So make the call the same day. This is not a reason to panic.
Both labels describe the same event. The main vein that drains your retina has become blocked. Blood and fluid back up into the retina, and the macula can swell1. The macula is the small central patch you read and recognize faces with. What separates the two labels is what happened to the retina's blood supply after that backup.
In a non-ischemic occlusion, blood still reaches the retinal tissue, even though the retina is congested and leaking. In an ischemic occlusion, wide patches of retina have stopped receiving blood at all. About 70 of every 100 central retinal vein occlusions are the non-ischemic kind2. The ischemic kind is defined by at least 10 disc areas of retinal capillary nonperfusion2. Those are large zones where the smallest vessels no longer fill.
The most immediate consequence of the label is how often you are seen over the next six months. A non-ischemic occlusion is commonly rechecked at around three months, while an ischemic one is usually watched monthly for the first six months2. That gap is not a judgment about how bad your vision is today.
It exists because of one complication: a form of glaucoma driven by new blood vessels. It shows up early in ischemic eyes, and it is far easier to control in its first weeks. The rest of this page covers what each type is, how your doctor sorts them out, and what changes in your care.
What Each Type of Central Retinal Vein Occlusion Actually Is
Your retina drains through a single vein that leaves the eye through the optic nerve. When a clot forms in that vein, drainage slows and pressure builds behind the blockage. Blood and fluid spill out into the retina, the macula can swell, and vision blurs in part or all of that eye, sometimes suddenly and sometimes over hours to days1. The eye itself usually looks normal from the outside, which is why the change is often noticed by covering the good eye.
Non-ischemic means the retina is congested but still fed. The tiny capillaries are stretched and leaky, so fluid pools in the macula and vision goes soft or wavy, but the retinal tissue is still getting oxygen. This is the more common presentation, making up roughly 70 of every 100 cases, and it typically comes with better starting vision, little or no pupil abnormality, and milder visual change than the ischemic form2. The swelling, not the loss of blood flow, is what limits sight.
Vision after a non-ischemic occlusion tends to track the swelling. It blurs when the macula is thick and clears as the macula settles. One systematic review pooled 53 studies covering 3,271 untreated eyes. Among the non-ischemic ones, macular swelling cleared on its own in roughly 30 of every 100, and later neovascular glaucoma was rare3. Waiting for that natural clearing is rarely the plan now. Treatment for the swelling works, and months of blur cost real function.
Ischemic means starved of blood. Here the blockage is severe enough that whole regions of capillary bed shut down and the retinal tissue in those regions loses its oxygen supply. The exam looks different too: extensive dark, deep retinal hemorrhages with multiple cotton-wool spots, an uneven pupil reaction called a relative afferent pupillary defect, and vision worse than 20/200 in more than 90 of every 100 such eyes4. Sight is limited by tissue that is no longer being supplied, not only by swelling.
Retina that is short of oxygen sends out chemical distress signals, chiefly a protein called VEGF. Those signals push the eye to sprout fragile new vessels. The trouble is where they sprout: on the iris and in the drainage angle, the mesh at the front of the eye that lets fluid out. In the Central Vein Occlusion Study, new vessels on the iris or in the angle appeared in about 35 of every 100 eyes classed as nonperfused or indeterminate, against about 10 of every 100 perfused eyes5. Blocking that drain is what turns an ischemic occlusion into a pressure problem.
Most people who walk in with a fresh central retinal vein occlusion have the non-ischemic form. Roughly 70 of every 100 are non-ischemic at presentation, and about 90 of every 100 eyes that see worse than 20/200 turn out to be ischemic2. That is why your starting vision is a strong early clue. It is also why no one should read their own chart line as a verdict. The middle range is genuinely mixed, and imaging settles it.
Ischemic vs. Non-Ischemic CRVO Side by Side
The table below lines up the features your retina specialist weighs. No single row decides it. The picture is read as a whole, and it can be revisited later.
| Feature | Non-ischemic CRVO | Ischemic CRVO |
|---|---|---|
| Share of cases at presentation. | About 70 of every 100. | About 30 of every 100. |
| Typical starting vision. | Often better than 20/200. | Worse than 20/200 in over 90 of every 100 eyes. |
| Pupil reaction. | Mild or no defect. | A relative pupil defect is usual. |
| Retinal appearance. | Milder bleeding. | Heavy deep bleeding, many cotton-wool spots. |
| Dye test finding. | Capillaries still fill. | At least 10 disc areas do not fill. |
Those rows come from the same body of work that defined the two groups24. If your chart says something you did not expect, ask about it directly.
The second table is about what happened to real eyes over months and years. That is a different question from how an eye looks today.
| What was followed | Non-ischemic | Ischemic |
|---|---|---|
| New vessels on iris or angle. | About 10 of every 100 eyes. | About 35 of every 100 eyes. |
| Neovascular glaucoma. | Rare. | At least 23 of every 100 eyes by 15 months. |
| Category change over 3 years. | Up to 34 of every 100 turned ischemic. | Does not revert. |
These are group averages drawn from studies of many eyes53. They say how often something happened in a population. They cannot tell you what will happen in your eye.
The labels are a snapshot, not a permanent assignment. In the Central Vein Occlusion Study, about 34 of every 100 eyes that started out perfused had converted to nonperfused by three years, with about 15 of every 100 converting within the first four months alone5. Conversion usually announces itself as a fairly sudden further drop in vision.
This is the best reason to keep appointments you feel fine for. The recheck is a short visit with imaging, not anything invasive.
How Your Retina Specialist Tells the Two Apart
Much of the answer comes from the dilated exam itself. Your doctor is reading how much blood is spread across the retina, how many cotton-wool spots are present, and how the optic nerve head looks. A relative afferent pupillary defect, found by swinging a light between the two eyes, and vision worse than 20/200 both point strongly toward the ischemic form, as does a reduced b-wave on an electroretinogram when that test is used4. None of this hurts, and none of it requires a needle.
Two imaging tests carry most of the weight. Optical coherence tomography is a light-based scan. It measures how much the macula has swelled1. Fluorescein angiography uses a dye given through an arm vein to photograph which capillaries still fill. A dye-free version of that scan can also be used1. The ischemic line is drawn at 10 or more disc areas that do not fill2. Expect the scan at most visits and the dye study less often.
Imaging describes the retina at the moment it was photographed. It does not forecast your vision a year out, and it cannot rule out a change of category later. Heavy retinal bleeding can also obscure the view, so perfusion cannot always be graded at the first visit. The Central Vein Occlusion Study kept an indeterminate group for eyes that could not be sorted cleanly, rather than forcing a label5. An honest 'we will know more in a month' is a normal answer here, not a stall.
How Treatment and Monitoring Differ Between the Two Types
Macular swelling is treated much the same way in both types, because the swelling itself responds to the same drugs. Intravitreal anti-VEGF injection is the first-line treatment for macular edema associated with a retinal vein occlusion6. In the SCORE2 randomized trial of 362 participants, monthly bevacizumab and monthly aflibercept each improved vision by about 19 letters on average at six months, and bevacizumab was noninferior to aflibercept7. A steroid implant placed in the eye is another option2.
Panretinal photocoagulation is a scatter laser that quiets the oxygen-starved retina so it stops sending growth signals. The question has been whether to apply it early, before new vessels appear. In the Central Vein Occlusion Study's randomized trial, laser given before new vessels developed did not significantly lower the rate of iris or angle new vessels8. New vessels cleared within a month of laser in about 56 of every 100 eyes not treated earlier, against about 22 of every 100 that had already had early laser, so the investigators favored close watching plus prompt laser once new vessels appear8. Ask how your own doctor weighs this alongside anti-VEGF.
Visit frequency is where the two types separate most sharply. Non-ischemic eyes are commonly rechecked at about three months, while ischemic eyes are typically seen monthly through the first six months, with monitoring for ischemia and swelling continuing up to about two years2. Those early visits include an undilated slit-lamp look at the iris and gonioscopy, a mirrored-lens view of the drainage angle, because that is where the first new vessels show up8. Injection visits are usually separate from these checks.
A retinal vein occlusion is partly a blood-vessel event, so the workup reaches beyond the eye. Blood pressure, blood sugar, lipids, and blood counts are checked in everyone2. A wider clotting and inflammatory workup is added for people under 50, for both-eye disease, or after past clots2. The known risk factors are high blood pressure, diabetes, open-angle glaucoma, and high cholesterol, and about 90 of every 100 patients are over 502. Treating those is care for your whole circulation.
Risks, Complications, and a Realistic Outlook
Starting vision is the most useful single predictor, at both ends of the range. In the Central Vein Occlusion Study, about 65 of every 100 eyes that began at 20/40 or better still saw in that range at the end of follow-up5. About 80 of every 100 eyes that began worse than 20/200 stayed worse than 20/200, and eyes in the middle band were mixed: some improved, some held, some declined5. Those figures come from an era before anti-VEGF injections, so they describe the untreated natural course, not what treatment adds.
The complication driving the monitoring schedule is neovascular glaucoma, in which new vessels block the eye's drain and pressure climbs. It developed in at least 23 of every 100 ischemic eyes within 15 months in pooled untreated data, while it was rare after non-ischemic occlusion3. In a modern cohort of 98 eyes, 13 went on to neovascular glaucoma at a median of roughly 198 days, and a relative afferent pupillary defect, worse starting vision, and high blood pressure were the significant predictors9. Caught at the new-vessel stage, it responds to laser more often than it does once it has taken hold8.
For a non-ischemic occlusion, the realistic hope is stable or better central vision once the swelling is treated. There is also a real chance of conversion, which follow-up is built to catch. For an ischemic occlusion, central vision often stays limited. The goal shifts toward protecting the eye from pressure damage and keeping it comfortable. Central retinal vein occlusion carries a higher risk of front-of-eye new vessels and neovascular glaucoma than the branch form6. Neither outlook is a prediction about you.
When to Call Your Eye Doctor After a Vein Occlusion
Some changes should not wait for your next scheduled visit. Aching or severe pain in the eye, redness with pain, rainbow halos around lights, or a sharp drop in vision over a day all deserve a call that day. Pain and pressure in the affected eye are recognized features of more severe disease1, and pressure driven by new vessels is what the early follow-up schedule is built to catch8.
When you call, say you have had a central retinal vein occlusion. Then describe what changed and when it started. That usually moves you to an urgent slot. Most such calls end in reassurance, and the ones that do not are the ones worth making.
Other changes are less urgent but still worth reporting before your next visit: blur creeping back after a good stretch, new distortion in straight lines, a fresh dark spot in the center of your view, or floaters rising steadily rather than suddenly. These often mean the macular swelling has returned and treatment is due sooner.
Report changes in the other eye too. It shares the same blood pressure, blood sugar, and eye pressure risks that set up the first event.
A central retinal vein occlusion is managed by an ophthalmologist, usually a retina specialist, because the imaging, injections, and laser all live in that specialty. Your optometrist or primary care doctor often stays involved for pressure checks, glasses, and the whole-body risk factors. If your eye pressure is being treated as well, a glaucoma specialist may join the team.
Ask who is tracking the interval between your visits. On an ischemic eye especially, an appointment that quietly slips from monthly to every few months is the gap this schedule exists to close.
Questions Patients Ask About Ischemic and Non-Ischemic CRVO
Ask your retina specialist directly; the answer is already in your chart. They combine your vision, the pupil test, how much blood and how many cotton-wool spots are on your retina, and the dye study that shows which capillaries still fill4. The formal line is drawn at 10 or more disc areas of nonperfusion2. If heavy bleeding blocks the view, you may be told it is indeterminate for now and rechecked once the blood clears.
Yes, on both counts that matter. Ischemic eyes start with worse vision and carry a substantially higher risk of new vessels and the glaucoma they cause. New vessels on the iris or angle appeared in about 35 of every 100 eyes in the poorly perfused group, against about 10 of every 100 perfused eyes5. That said, 'more serious' means closer monitoring and a different set of goals, not that nothing can be done.
It can, and that possibility is the reason for follow-up. In the Central Vein Occlusion Study, about 34 of every 100 initially perfused eyes converted within three years5. Roughly 15 of every 100 converted in the first four months5. Conversion usually shows up as a clear further drop in vision. Report any sudden worsening rather than waiting for your next visit.
It depends heavily on where your vision started and on how the macular swelling responds. Roughly 65 of every 100 eyes that began at 20/40 or better held that range in untreated follow-up, while about 80 of every 100 that began worse than 20/200 stayed there5. With monthly injections for swelling, average gains of about 19 letters at six months were seen in a randomized trial7. Group averages, not a forecast for your eye.
More Questions About Living With a CRVO Diagnosis
Injections treat macular swelling, and swelling can be present while your vision still reads reasonably well, especially early. Treating it while vision is good is aimed at protecting what you have rather than rescuing what is lost. Anti-VEGF injection is the first-line treatment for the swelling that follows a vein occlusion6. If you are unsure why yours was recommended, ask to see your scan. The thickness number is easy to follow visit to visit.
The other eye does not inherit the clot, but it shares the conditions that set the stage for it. High blood pressure, diabetes, open-angle glaucoma, and high cholesterol are the recognized risk factors, and the great majority of patients are over 502. Keeping those conditions controlled is the most useful thing you can do for the second eye. Any sudden blur in it deserves a prompt exam.
Usually not. Scatter laser is aimed at oxygen-starved retina and at new vessels, and new-vessel complications are rare in non-ischemic eyes4. Even in ischemic eyes, one randomized trial found that laser given before new vessels appeared did not significantly lower the rate of iris and angle new vessels8. That is why close watching, with prompt laser at the first sign of new vessels, is the usual approach. Your own plan may differ.
Work the shared risk factors with your primary care doctor: blood pressure, blood sugar, and cholesterol, plus not smoking. Blood pressure, glucose, lipids, and blood counts are checked in everyone with this diagnosis, with a wider clotting workup for people under 50, both-eye involvement, or a history of clots2. Keep your eye pressure checked too, since open-angle glaucoma is on that risk list. None of this is a guarantee, and it is still the strongest lever you hold.
- Is my occlusion ischemic, non-ischemic, or still indeterminate, and what did you use to decide?
- How many disc areas of nonperfusion did my dye study show?
- How often should I be seen over the next six months, and who tracks that interval?
- Will my visits include a check of my iris and drainage angle for new vessels?
- What change in my vision should make me call you the same day?
- Which of my other health conditions should I be working on, and with whom?
- American Academy of Ophthalmology (EyeSmart) (2024). What Is Central Retinal Vein Occlusion (CRVO)?.
- StatPearls, NCBI Bookshelf (2023). Central Retinal Vein Occlusion (StatPearls).
- Ophthalmology, systematic review (PMID 20430446) (2010). Natural History of Central Retinal Vein Occlusion: An Evidence-Based Systematic Review.
- American Academy of Ophthalmology, EyeNet Magazine (2021). Diagnosis and Management of Central Retinal Vein Occlusion.
- The Central Vein Occlusion Study Group, Archives of Ophthalmology (PMID 9109757) (1997). Natural history and clinical management of central retinal vein occlusion (Central Vein Occlusion Study).
- American Academy of Ophthalmology Preferred Practice Pattern Retina/Vitreous Committee, Ophthalmology (PMID 39918523) (2025). Retinal Vein Occlusions Preferred Practice Pattern.
- JAMA, randomized noninferiority trial (2017). Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial.
- The Central Vein Occlusion Study Group, Ophthalmology (PMID 9097789) (1995). A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion (CVOS Group N Report).
- American Journal of Ophthalmology, retrospective cohort (PMC6642681) (2019). Predictors of Neovascular Glaucoma in Central Retinal Vein Occlusion.